1887

n Cardiovascular Journal of South Africa - COMET challenges paradigm of ACE inhibition in mild heart failure : drug trends in cardiology

USD

 

Abstract

Extracted from text ... COMET challenges paradigm of ACE inhibition in mild heart failure 'The results of the COMET study in chronic heart failure show the clear survival benefits of carvedilol (Dilatrend(r)) to a level far greater than anyone had anticipated', noted Prof. P. Poole- Wilson, Chairman of the Steering Committee of the COMET Study at the recent presentation of final results in Strasbourg. South African primary-care physicians were also recently given the opportunity to view these results via video during a satellite CME on heart failure treatment presented by leading South African specialists with sponsorship from Roche Pharmaceuticals. Focusing firstly on the remodelling ..

Loading

Article metrics loading...

/content/cardio/14/4/EJC23850
2003-07-01
2016-12-04
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error